Basepair

Executive Summary

Basepair is a US-based bioinformatics company offering a cloud-native SaaS platform for next-generation sequencing (NGS) data analysis. Founded in 2015 and headquartered in New York, the company differentiates itself with a federated model that deploys within a customer's AWS account, eliminating data movement and enhancing security. The platform serves academic, commercial, and clinical research sectors, providing an intuitive interface, advanced visualization, and support for custom workflows. By addressing the growing need for scalable, secure, and user-friendly NGS analysis, Basepair positions itself as a key enabler in genomics research and diagnostics. The company operates in a rapidly expanding market driven by decreasing sequencing costs and increasing adoption of precision medicine. Basepair’s business model, with deployment within customer cloud accounts, addresses critical data sovereignty concerns, particularly in clinical and pharmaceutical settings. While not yet widely recognized, the platform has the potential to capture significant market share by simplifying complex bioinformatics pipelines. The company remains private with no disclosed funding, suggesting a lean operation or early stage. Its long-term success hinges on securing key partnerships and expanding its customer base beyond early adopters.

Upcoming Catalysts (preview)

• TBDMajor pharmaceutical partnership for clinical trial support30% success
• TBDFDA clearance or CLIA certification for clinical diagnostic use20% success
• TBDSeries A funding round to accelerate growth40% success